Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Interest & Investment Income: 2020-2024

Historic Interest & Investment Income for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • SAB Biotherapeutics' Interest & Investment Income rose 136.40% to $655,233 in Q3 2025 from the same period last year, while for Sep 2025 it was $867,667, marking a year-over-year decrease of 46.89%. This contributed to the annual value of $1.3 million for FY2024, which is 119.84% up from last year.
  • As of FY2024, SAB Biotherapeutics' Interest & Investment Income stood at $1.3 million, which was up 119.84% from $584,966 recorded in FY2023.
  • SAB Biotherapeutics' 5-year Interest & Investment Income high stood at $1.3 million for FY2024, and its period low was $23,115 during FY2021.
  • For the 3-year period, SAB Biotherapeutics' Interest & Investment Income averaged around $647,345, with its median value being $584,966 (2023).
  • As far as peak fluctuations go, SAB Biotherapeutics' Interest & Investment Income dropped by 11.54% in 2021, and later spiked by 723.06% in 2023.
  • SAB Biotherapeutics' Interest & Investment Income (Yearly) stood at $26,131 in 2020, then dropped by 11.54% to $23,115 in 2021, then skyrocketed by 207.47% to $71,072 in 2022, then skyrocketed by 723.06% to $584,966 in 2023, then spiked by 119.84% to $1.3 million in 2024.